• Strengthening of the cash position to €23.9 million as of June 30, 2022 following the receipt of a milestone payment of $5 million from Tonghua Dongbao (THDB) received in May 2022
• Sharp increase in half-year revenue to €7.3 million (vs. €0.4 million in the 1st half of 2021), following the achievement of major milestones in the second quarter:
o $5 million milestone payment triggered by first patient dosing in pivotal Phase 3 clinical trial in China of ultra-rapid insulin BC Lispro
o Collaborative revenue of €2.2 million for the conduct of 3 clinical studies conducted in Europe with BC Combo, a combination of basal and prandial insulins
6:00 p.m. CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, publishes its cash position and revenue. business for the second quarter and first half of 2022 and provides an update on its activities.